NCT04353765View on ClinicalTrials.gov

Study Of Cabozantinib Treatment In Patients With Unresectable, Locally Advanced Or Metastatic Renal Cell Carcinoma Who Progressed After Previous Treatment With Checkpoint Inhibitors

CompletedOBSERVATIONAL
Enrollment

247

Participants

Timeline

Start Date

January 30, 2020

Primary Completion Date

June 5, 2020

Study Completion Date

June 5, 2020

Conditions
Locally Advanced or Metastatic Renal Cell Carcinoma
Interventions
DRUG

Cabozantinib monotherapy

Intervention description (FDA Label): kinase inhibitor indicated for the treatment of patients with advanced renal cell carcinoma (RCC).

DRUG

All authorized TKI monotherapies in advanced RCC per FDA label in advanced RCC

As per authorized FDA label in advanced RCC

Trial Locations (1)

77380

McKesson Life Sciences, The Woodlands

Sponsors

Lead Sponsor

Ipsen
All Listed Sponsors
lead

Ipsen

INDUSTRY